caplacizumab (cablivi) Report issue

Biologics mAb Orphan Drug FDA Approved FDA Fast Track FDA
AACT ChEMBL Drugs@FDA MeSH

Active Ingredient History

NOW
  • Now
Caplacizumab is a bivalent single-domain antibody (VHH) designed for the treatment of thrombotic thrombocytopenic purpura (TTP) and thrombosis.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

alx-0081 | anti-vwf nanobody | caplacizumab | caplacizumab-yhdp

Organizations (3)

Research & Development (3)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Angina Pectoris (Phase 2)

Angina, Unstable (Phase 2)

Healthy Volunteers (Phase 1)

Purpura (Phase 3)

Purpura, Thrombotic Thrombocytopenic (Phase 2/Phase 3)

ST Elevation Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial Organizations: 3

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue